Australia's Mesoblast jumps as USFDA plans inspection of its cell therapy ops

Mesoblast

22/03/2023 02:46

** Shares of Mesoblast Ltd  MSB.AX  jump as much as 5% to
A$0.94, on track for best day since March 8, if gains hold
    ** Regenerative medicine maker says the USFDA has scheduled
pre-license inspection of cell therapy manufacturing operations
at Lonza Bioscience in Singapore
    ** Inspection part of ongoing review of Remestemcel-L for
treatment of children with pediatric acute graft-versus-host
disease
    ** USFDA had on March 7 accepted co's biologics license
application resubmission for the cellular therapy
    ** Stock up 2.9% this year, as of last close

 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com;))